Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold2
Sell2
Strong Sell1

Share price forecast in EUR

The 5 analysts offering 12 month price targets for Fresenius Medical Care AG (ADR) have a median target of 22.38, with a high estimate of 27.44 and a low estimate of 17.48. The median estimate represents a 5.07% increase from the last price of 21.30.
High28.8%27.44
Med5.1%22.38
Low-17.9%17.48

Dividends in EUR

Historical dividend information is not available for Fresenius Medical Care AG.
Div growth (TTM)--
More ▼

Earnings history & estimates in EUR

On Jul 30, 2024, Fresenius Medical Care AG (ADR) reported 2nd quarter 2024 earnings of 0.24 per share.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate+0.68%
Fresenius Medical Care AG (ADR) reported annual 2023 earnings of 1.29 per share on Feb 20, 2024.
Average growth rate-12.53%
More ▼

Revenue history & estimates in EUR

Fresenius Medical Care AG (ADR) had 2nd quarter 2024 revenues of 4.77bn. This missed the 4.82bn consensus estimate of the 2 analysts following the company. This was 1.32% above the prior year's 2nd quarter results.
Average growth rate-0.26%
Fresenius Medical Care AG (ADR) had revenues for the full year 2023 of 19.45bn. This was 0.29% above the prior year's results.
Average growth rate+2.81%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.